AIM: The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors. PATIENTS & METHODS: We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset and CAD risk factors or cardiovascular comorbidities. RESULTS: Eighty-seven pts were enrolled, with median treatment duration of 9 months (1-44). At baseline, 84 pts (96%) had CAD risk factors. During treatment four pts (4; 6%) developed hypertension and 26 pts (30%) worsened the preexisting hypertension. Median left ventricular ejection fraction were 64 and 63% at baseline and after treatment, respectively. CONCLUSION: AA appears to be safe in pts with cardiovascular comorbidities or CAD risk factors

Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: A prospective evaluation

Aversa, Caterina;Galizia, Danilo;TORINO, SOFIA;NUZZOLESE, IMPERIA;MARANDINO, LAURA;Aglietta, Massimo;
2018-01-01

Abstract

AIM: The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors. PATIENTS & METHODS: We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset and CAD risk factors or cardiovascular comorbidities. RESULTS: Eighty-seven pts were enrolled, with median treatment duration of 9 months (1-44). At baseline, 84 pts (96%) had CAD risk factors. During treatment four pts (4; 6%) developed hypertension and 26 pts (30%) worsened the preexisting hypertension. Median left ventricular ejection fraction were 64 and 63% at baseline and after treatment, respectively. CONCLUSION: AA appears to be safe in pts with cardiovascular comorbidities or CAD risk factors
14
5
443
448
http://www.futuremedicine.com/loi/fon
abiraterone acetate; cardiovascular risk factors; frail patients; metastatic castration-resistant prostate cancer; multidisciplinary management; prospective study; safety; Oncology; Cancer Research
Prati, Veronica; Ruatta, Fiorella; Aversa, Caterina; Gernone, Angela; Galizia, Danilo; Bonzano, Alessandro; Torino, Sofia; Nuzzolese, Imperia; Marandino, Laura; Aglietta, Massimo; Ortega, Cinzia
File in questo prodotto:
File Dimensione Formato  
Crt Rev Oncol Hematol 2018.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 354.77 kB
Formato Adobe PDF
354.77 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1663857
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact